- Home
- ASGN vs VRNA Comparison
ASGN vs VRNA Comparison
Compare ASGN & VRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASGN
- VRNA
- Stock Information
- Founded
- ASGN 1985
- VRNA 2005
- Country
- ASGN United States
- VRNA United Kingdom
- Employees
- ASGN N/A
- VRNA N/A
- Industry
- ASGN Professional Services
- VRNA Biotechnology: Pharmaceutical Preparations
- Sector
- ASGN Consumer Discretionary
- VRNA Health Care
- Exchange
- ASGN Nasdaq
- VRNA Nasdaq
- Market Cap
- ASGN 4.2B
- VRNA 3.4B
- IPO Year
- ASGN 1992
- VRNA 2017
- Fundamental
- Price
- ASGN $88.43
- VRNA $51.89
- Analyst Decision
- ASGN Buy
- VRNA Strong Buy
- Analyst Count
- ASGN 4
- VRNA 7
- Target Price
- ASGN $101.75
- VRNA $50.57
- AVG Volume (30 Days)
- ASGN 313.2K
- VRNA 1.4M
- Earning Date
- ASGN 02-05-2025
- VRNA 02-27-2025
- Dividend Yield
- ASGN N/A
- VRNA N/A
- EPS Growth
- ASGN N/A
- VRNA N/A
- EPS
- ASGN 3.96
- VRNA N/A
- Revenue
- ASGN $4,188,800,000.00
- VRNA $5,624,000.00
- Revenue This Year
- ASGN N/A
- VRNA N/A
- Revenue Next Year
- ASGN $1.86
- VRNA $550.30
- P/E Ratio
- ASGN $22.34
- VRNA N/A
- Revenue Growth
- ASGN N/A
- VRNA 1127.95
- 52 Week Low
- ASGN $82.04
- VRNA $11.39
- 52 Week High
- ASGN $106.42
- VRNA $55.42
- Technical
- Relative Strength Index (RSI)
- ASGN 55.27
- VRNA 64.25
- Support Level
- ASGN $84.87
- VRNA $43.44
- Resistance Level
- ASGN $87.02
- VRNA $55.42
- Average True Range (ATR)
- ASGN 1.97
- VRNA 3.32
- MACD
- ASGN 0.72
- VRNA 0.40
- Stochastic Oscillator
- ASGN 75.73
- VRNA 70.52
About ASGN ASGN Incorporated
ASGN Inc is a provider of information technology (IT) services and professional solutions, including technology, creative, and digital, across the commercial and government sectors. It operates through two segments, Commercial and Federal Government. The Commercial Segment, which generates the majority of the revenue, provides consulting, creative digital marketing, and permanent placement services to Fortune 1000 clients and mid-market companies. The Federal Government Segment provides mission-critical solutions to the Department of Defense, intelligence agencies, and civilian agencies.
About VRNA Verona Pharma plc
Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. The company is currently focusing on developing its Ensifentrine product candidate, which will treat chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and other respiratory diseases, including asthma.